Gene Transfer Trial for Cancer
Phase 1/2
124
about 11 years
18–72
1 site in MD
About this study
This trial is testing a new way to treat cancer by modifying blood cells with a special gene. Researchers are giving these modified cells back to patients who have CD70-expressing cancers like breast, melanoma, ovarian, pancreatic, or renal cell cancer. The goal is to see if this treatment can safely shrink tumors and determine its safety.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Anti-hCD70 CAR transduced PBL
- 2.Take Aldesleukin
- 3.Take Cyclophosphamide
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
aldesleukin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Frequency and severity of treatment-related adverse events, Response rate
Secondary: Frequency and severity of treatment-related adverse events
Oncology